2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1818

Latent Tuberculosis Detection and Tuberculosis Reactivation in Patients Receiving Anti-TNFá Drugs: A Nationwide Italian Survey
Abstract Number: 173

Latent Tuberculosis Screening and Treatment in Rheumatoid Arthritis Patients Eligible for Anti-TNF Therapy in Endemic Areas: Does It Work?
Abstract Number: 1105

Lateral Tibio-Femoral Shift Related to Medial Knee Osteoarthritis
Abstract Number: 956

Learning Disability in Fibromyalgia Patients: FMS Patients Report More Language and Spatial Difficulties
Lee C. Howley Sr. Prize for Arthritis Research Introductory Talk I
Lee C. Howley Sr. Prize for Arthritis Research Introductory Talk II
Abstract Number: 1458

Left Ventricular Diastolic Dysfunction May Play a Role in Pathophysiology and Poor Prognosis of Pulmonary Arterial Hypertension Associated with Systemic Sclerosis
Abstract Number: 720

Left-Heart Disease Is a Frequent Cause of Pulmonary Hypertension in Systemic Sclerosis, Is Associated with Increased Levels of MR-ProANP and MR-ProADM but Is Unrelated to Elevated NT-ProBNP Levels: A Retrospective Cohort Analysis
Abstract Number: 791

Leg Muscle Mass Is Not Affected by Foot Pain, Structure or Function: The Framingham Foot Study
Abstract Number: 74

Length of Stay for Rheumatoid Arthritis Related Orthopedic Surgery Has Improved Over the Past 3 Decades and Is Related to Disease Markers. Results From Two UK Multicentre Inception Cohorts (1986-2011) Compared with National Data
Abstract Number: 666

Leukadherin 1, a CR3 Mimetic, Negatively Regulates Toll Like Receptor (TLR) Dependent Inflammatory Responses via Degradation of an Adaptor Protein
Abstract Number: 29

Level of IL-1â-Induced Epigenetic Modifications Differ in Chondrocytes From Different Histological Zones of Human Cartilage
Abstract Number: 818

Levotofisopam Has Uricosuric Activity and Reduces Serum Urate Levels in Patients with Gout
Abstract Number: 599

LIGHT (TNFSF14), Cathepsin K, DKK-1 and Sclerostin in Ankylosing Spondylitis: Osteoclast/OSTEOBLAST Imbalance Unrelated to Disease Activity and Effect of ANTI-TNFα Treatment On the WNT/β Catenin Pathway
Abstract Number: 498

LIGHT (TNFSF14), Cathepsin-K, DKK-1 and Sclerostin in Rheumatoid Arthritis Patients: Effect of ANTI TNF-α Treatment in the WNT/β-Catenin Network Signaling

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].